THB, a leading real-world evidence company in the Asia Pacific, with partnerships with over 3000 care delivery centers is now strengthening its focus on Diabetes in collaboration with RSSDI (Research Society for the Study of Diabetes in India). On the occasion of National Doctors Day on 1st July, the two organizations have announced their partnership to drive hassle-free research in Diabetes with a vision to generate cutting-edge clinical trends on one of the largest diabetes markets, and leverage clinical evidence to drive personalized care, and deliver tangible data-backed clinical improvements.
Diabetes is one of the largest healthcare challenges worldwide. The global incidence of diabetes was estimated at 9.3%, 463 million people in 2019 and predicted to increase to 10.9%, 700 million people by 2040, by International Diabetes Federation. India remains the second most affected country(after China) in the world, with 77 million diabetes patients and an estimated 36.5 million patients with prediabetes. The disease – being chronic and progressive in nature – inflicts substantial cost of treatment on the patient and their families, and in other cases on the payors.
Real-world Evidence is the latest global theme that is enabling organizations to analyze and review patterns from millions of clinical records of existing diabetes patients. Real-World evidence enables understanding of disease burden across micro-markets, degree of under-diagnosis and under-treatment, lack of compliance, preference of molecules basis patient cohorts and complaints, drivers of treatment switching, the effectiveness of molecules in the real world, cost economics of treatments basis total cost and net clinical improvement, and most importantly, drivers of improvement and deterioration of clinical outcomes in real-world settings.
Lavina Yadav, Head of RWE Strategy and Operations, says – “We are honored to be working with RSSDI to expand the generation and adoption of real-world evidence in Diabetes. With the size of the country, and the extent of diabetes prevalence, we believe that this collaboration has the power to make India the largest producer of medical research on Diabetes in the world”.
Dr BanshiSaboo, President, RSSDI, and Dr Sanjay Agarwal, Secretary RSSDI say – “We are glad to be working with THB, and are very happy that THB is playing a front-runner role in Real-World Evidence in Diabetes along with RSSDI. Over the next few years, we aim to publish 100+ research articles, drive education across 100K+ physicians, and provide evidence-based care across 1m+ diabetes patients along with THB.”